BIT Capital’s Alpine Immune Sciences Inc ALPN Stock Holding History

BIT Capital’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,000	Closed	-$43.2K	–	190
2022 Q3	$43.2K	Buy	+6,000	New	+$49.5K	0.01%	137

Other funds holding ALPN

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BIT Capital's ALPN Position: Q4 2022 in Review

BIT Capital sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2022, closing a stake of 6,000 shares — an estimated $43.2K sold.

BIT Capital first reported a position in ALPN in Q3 2022 and held it in 1 quarter. The position peaked at $43.2K in Q3 2022. 63 funds tracked by Wall St. Rank hold ALPN as of Q4 2022.

BIT Capital reported no remaining Alpine Immune Sciences Inc position as of Q4 2022 after selling out during the quarter.
BIT Capital sold 6,000 Alpine Immune Sciences Inc shares in Q4 2022, an estimated $43.2K.
BIT Capital first reported a position in Alpine Immune Sciences Inc in Q3 2022 and held it in 1 quarter.
BIT Capital's Alpine Immune Sciences Inc position peaked at $43.2K in Q3 2022.
63 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2022.

Based on BIT Capital's 13F filing for Q4 2022, filed 12 Feb 2025.